

JUL 27 2004 11:05AM

AVENTIS US PAT DEPT

RECEIVED
CENTRAL FAX CENTER

OFFICIAL

JUL 27 2004

**FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE**

Applicants Docket Number:
DEAV2001/0006 US NP

Applicants:
STROBEL, et al.

Serial No.
10/073,203

Filing Date:
02/13/2002

Title of Invention:
**ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL AMINES AND THEIR USE AS
PHARMACEUTICAL AGENTS**

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, Examiner KIFLE, at 703-872-9306, on

Date of Deposit July 27, 2004

Printed Name of Person Signing Certificate Rene McGinnis

Signature Rene McGinnis

Total Number of Pages Sent: 2

Attorney: Raymond S. PARKER, III

Group Art Unit: 1624

Examiner: Bruck KIFLE

TO: Mail Stop
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by return telefax to
(908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of
Aventis Pharmaceuticals Inc.

- | | |
|--|--|
| <input type="checkbox"/> Amendment, 37 CFR _____ | <input type="checkbox"/> Fee Transmittal |
| <input type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input type="checkbox"/> Extension of Time Petition | <input checked="" type="checkbox"/> Other <u>Change of Correspondence
Address Form</u> |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input type="checkbox"/> Other _____ |
| <input type="checkbox"/> Maintenance Fee Transmittal | |

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. reprint (March 2001)

JUL 27 2004 11:05AM

AVENTIS US PAT DEPT CENTRAL FAX CENTER

RECEIVED

OFFICIAL

NO. 5760 P. 2

JUL 27 2004

PTO/SB/123 (09-03)

Approved for use through 11/30/2005. OMB 0651-0036

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**CHANGE OF
CORRESPONDENCE ADDRESS
Patent**Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450.

Patent Number	6,759,412
Issue Date	July 6, 2004
Application Number	10/073,203
Filing Date	February 13, 2002
First Named Inventor	STROBEL, et al.
Attorney Docket Number	DEAV2001/0006 US NP

Please change the Correspondence Address for the above-identified patent application to:



Customer Number:

OR

Firm or
Individual NameAVENTIS PHARMA DEUTSCHLAND GMBH
ATTN: Mr. Markus Jacobi

Address

Industriepark Hoechst

Address

Gebäude K 802

City

Frankfurt am Main

State

Zip

65926

Country

GERMANY

Telephone

Fax

This form cannot be used to change the data associated with a Customer Number. To change the data associated with an existing Customer Number use "Request for Customer Number Data Change" (PTO/SB/124).

This form will not affect any "fee address" provided for the above-identified patent. To change a "fee address" use the "Fee Address Indication Form" (PTO/SB/47).

I am the:



Patentee.

Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed (Form PTO/SB/96).

Attorney or Agent of record. Registration Number 34,893

Typed or Printed
Name

Raymond S. Parker, III, Ph.D., Reg. No. 34,893

Signature

Date

Telephone

908-231-5674

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.



Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P. O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

Aventis Pharmaceuticals Inc. template